Farmington, Connecticut 06030

  • Breast Cancer


This single arm study will evaluate the efficacy, safety and impact on quality of life of treatment with oral Xeloda plus intravenous Taxotere (docetaxel) in patients with HER2-neu negative breast cancer, and in combination with iv Herceptin (trastuzumab) in patients with HER2-neu positive breast cancer. Patients will receive 3-weekly cycles of treatment with Xeloda (825mg/m2 po bid on days 1-14) + Taxotere (75mg/m2 iv on day 1). HER2-neu positive patients will also receive Herceptin (loading dose of 4mg/kg iv followed by 2mg/kg iv weekly). The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Inclusion Criteria: - women >=18 years of age; - newly diagnosed; - infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer. Exclusion Criteria: - evidence of metastatic disease, except ipsilateral (same side) axillary lymph nodes; - previous systemic or local primary treatment.

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

Official Title:

An Open-label Study of Xeloda Plus Taxotere on Treatment Response in Patients With HER2-neu-negative, and the Addition of Herceptin for HER2-neu-positive Breast Cancer

Overall Status:


Study Phase:

Phase 4



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Hoffmann-La Roche

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Clinical Trials
Study Director
Hoffmann-La Roche

Study Dates

Completion Date:July 2009
Completion Type:Actual
Verification Date:November 2009
Last Changed Date:November 16, 2009
First Received Date:August 5, 2005

Study Outcomes

Outcome Type:Primary Outcome
Measure:Pathological complete response in primary breast tumor at time of definitive surgery
Time Frame:Event driven
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Complete pathological response, overall clinical response, local recurrence, disease-free and overall survival.
Time Frame:Event driven
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:AEs, laboratory parameters
Time Frame:Throughout study
Safety Issues:False

Study Interventions

Intervention Type:Drug
Name:capecitabine [Xeloda]
Description:825mg/m2 po bid on days 1-14 of each 3 week cycle
Arm Name:1
Intervention Type:Drug
Description:75mg/m2 iv on day 1 of each 3 week cycle
Arm Name:1
Intervention Type:Drug
Description:4mg/kg iv (loading dose) followed by 2mg/kg iv weekly (only HER2-neu positive patients)
Arm Name:1

Study Arms

Study Arm Type:Experimental
Arm Name:1

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Hoffmann-La Roche

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.